Brokerage Firms Issue Key Ratings on Indian Stocks Amid Market Volatility
In a series of recent analyst reports, major financial institutions have updated their ratings and target prices for several prominent Indian companies, highlighting both opportunities and risks in the current economic climate.
ITC Faces Uncertainty Due to Tax Increases
Morgan Stanley has assigned an equal weight rating to ITC, setting a target price of Rs 346. Analysts noted that the sharp tax increases are unprecedented and are creating significant uncertainty in the market. ITC shares have declined by 25% so far this year, compared to a 10% loss in the Sensex. They believe that incremental pricing actions and the impact on volumes and earnings before interest and taxes (EBIT) growth in the April-June quarter (Q1FY27) could serve as key catalysts for the stock.
HSBC Upgrades Max Healthcare to Buy
HSBC has upgraded Max Healthcare to a buy rating, raising the target price to Rs 1,125 from Rs 1,060. Analysts expressed confidence that Max Healthcare has ample growth drivers to support earnings growth. They project a compounded annual growth rate (CAGR) for earnings per share (EPS) of 28.5% for the FY26 to FY28 period. The robust growth outlook and execution capabilities are seen as outweighing short-term issues.
Key positives for the stock include:
- Net addition of 2,240 beds (a 43% capacity increase) between now and FY28, with 60% being brownfield beds.
- Economies of scale benefits from brownfield additions.
- Scale-up of recent large format hospitals in Noida and Dwarka.
- Access to a large pool of CGHS patients, helping to quickly fill occupancy and cover fixed costs at new hospitals.
UBS Initiates Neutral Rating on Coforge
UBS has initiated coverage on Coforge with a neutral rating and a target price of Rs 1,240. Analysts acknowledged that Coforge has consistently delivered strong growth driven by execution, with organic growth of about 13-15% over FY24-FY25 and overall growth of about 15-30%. They estimate a revenue CAGR of 15% over FY26-FY28. The stock has corrected by 35% year-to-date, making its price-earnings growth ratio of 0.8x appear attractive.
However, analysts have raised some concerns:
- The acquisitive nature of the company, with persistent concerns around dilution and integration.
- A relatively weaker positioning for Generative AI according to the VECTOR framework.
As a result, analysts believe the risk-reward profile is balanced for now.
Macquarie Sees Outperform for L&T Despite West Asian Tensions
Macquarie has assigned an outperform rating to Larsen & Toubro (L&T) with a target price of Rs 4,910. Analysts reported that none of L&T's project sites have been affected by the West Asian conflict so far. Approximately 95% of sites continue to operate, while 5% have been stalled by the company or clients due to risk factors such as proximity to military bases. These stalled sites currently do not contribute significantly to L&T's revenue.
The company's deputy managing director has flagged logistics and supply chain as key challenges, highlighting revenue risks including potential deferments if the situation is not resolved within three months, as the company typically maintains a three-month supply at sites. The stock has corrected over 22% in the last month, and analysts see significant value at current levels.
Goldman Sachs Maintains Buy on Indigo Amid Challenges
Goldman Sachs has maintained its buy rating on InterGlobe Aviation (Indigo) but revised the target price down to Rs 5,200 from Rs 6,000. Analysts sharply cut estimates due to higher fuel costs and noted that West Asia traffic weakness is impacting the near-term outlook. They also suggested there could be some industry consolidation due to supply constraints.
The company's net cash balance sheet is viewed as a key strength, and analysts expect market share gains as weaker players exit the industry.
